A) For what condition did the FDA approve this drug? B) How many aromatic rings does this drug contain? C) How many "true" lone pairs does this drug contain? D) How many aromatic pi electrons does this drug contain?
Reactive Intermediates
In chemistry, reactive intermediates are termed as short-lived, highly reactive atoms with high energy. They rapidly transform into stable particles during a chemical reaction. In specific cases, by means of matrix isolation and at low-temperature reactive intermediates can be isolated.
Hydride Shift
A hydride shift is a rearrangement of a hydrogen atom in a carbocation that occurs to make the molecule more stable. In organic chemistry, rearrangement of the carbocation is very easily seen. This rearrangement can be because of the movement of a carbocation to attain stability in the compound. Such structural reorganization movement is called a shift within molecules. After the shifting of carbocation over the different carbon then they form structural isomers of the previous existing molecule.
Vinylic Carbocation
A carbocation where the positive charge is on the alkene carbon is known as the vinyl carbocation or vinyl cation. The empirical formula for vinyl cation is C2H3+. In the vinyl carbocation, the positive charge is on the carbon atom with the double bond therefore it is sp hybridized. It is known to be a part of various reactions, for example, electrophilic addition of alkynes and solvolysis as well. It plays the role of a reactive intermediate in these reactions.
Cycloheptatrienyl Cation
It is an aromatic carbocation having a general formula, [C7 H7]+. It is also known as the aromatic tropylium ion. Its name is derived from the molecule tropine, which is a seven membered carbon atom ring. Cycloheptatriene or tropylidene was first synthesized from tropine.
Stability of Vinyl Carbocation
Carbocations are positively charged carbon atoms. It is also known as a carbonium ion.
![NH₂
Imbruvica
ABBVIE WINS
PHARMACYCLICS
PHARMACEUTICALS: $21 billion
deal helps firm become a leader
in treating blood cancers
UST MONTHS AFTER abandoning its $54 bil-
lion bid for specialty drug maker Shire, AbbVie
is shelling out $21 billion for Sunnyvale, Calif.
based Pharmacyclics. The purchase furthers AbbVie's
ambitions in the field of hematological cancer and re-
duces its reliance on one major product.
The hefty price tag is the result of heated competi-
tion. "I've been through a lot of these, and I'd say this is
one of the most competitive ones I've seen." AbbVie's
CEO Richard A. Gonzalez said on a March 5 call with
investors. Three companies were bidding against each
other until the bitter end, he said. Indeed, just hours
before the deal was announced, some media outlets re
ported that Johnson & Johnson had won out.
Pharmacyclics's key asset is Imbruvica, a BTK inhibi-
tor acquired in 2006 from Celera Genomics for just
6
$2 million and some equity. FDA approved Imbravica
in late 2013 to treat mantle cell leukemia, and the drug
has since won the agency's nod in three other blood
cancers. It is expected to bring in $1 billion in sales this
year for Pharmacyclics and its marketing partner J&J.
Imbruvica represents "a pipeline in a molecule,
much like Humira did," Gonzalez said. AbbVie's Humi-
ra is the world's top-selling drug, bringing in $12.5 bil-
lion in sales last year across a range of inflammatory
diseases, but its patent is set to expire in late 2016.
AbbVie believes its portion of peak sales for Imbruvica
could exceed $7 billion per year.
The deal also advances AbbVie's goal of becom-
ing a powerhouse in treating hematological cancer, a
market worth $24 billion in 2014. AbbVie sees syner-
gies between Imbruvica and two small molecules in its
pipeline: ABT-199, which blocks Bel-a and is in Phase
Il studies to treat acute myelogenous leukemia and
duvelisib, a PI3K inhibitor in Phase II studies to treat
several blood cancers.
Last October, AbbVie walked away from the Shire
deal after a change in U.S. tax law. Gonzalez said the
two deals are strategically "very different." Shire was
viewed as an avenue to lowering AbbVie's tax base,
whereas Pharmacyclics complements its oncology
portfolio LISA JARVIS](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2F61cdf54b-d018-4e7a-a9ae-13d90fb36fd7%2F6b95ad41-d5c9-4283-9329-4fca1bf49449%2F4wcc8tv_processed.jpeg&w=3840&q=75)
![A) For what condition did the FDA approve this drug?
B) How many aromatic rings does this drug contain?
C) How many "true" lone pairs does this drug contain?
D) How many aromatic pi electrons does this drug contain?](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2F61cdf54b-d018-4e7a-a9ae-13d90fb36fd7%2F6b95ad41-d5c9-4283-9329-4fca1bf49449%2Fsljvk6t_processed.jpeg&w=3840&q=75)
![](/static/compass_v2/shared-icons/check-mark.png)
Step by step
Solved in 4 steps
![Blurred answer](/static/compass_v2/solution-images/blurred-answer.jpg)
![Chemistry](https://www.bartleby.com/isbn_cover_images/9781305957404/9781305957404_smallCoverImage.gif)
![Chemistry](https://www.bartleby.com/isbn_cover_images/9781259911156/9781259911156_smallCoverImage.gif)
![Principles of Instrumental Analysis](https://www.bartleby.com/isbn_cover_images/9781305577213/9781305577213_smallCoverImage.gif)
![Chemistry](https://www.bartleby.com/isbn_cover_images/9781305957404/9781305957404_smallCoverImage.gif)
![Chemistry](https://www.bartleby.com/isbn_cover_images/9781259911156/9781259911156_smallCoverImage.gif)
![Principles of Instrumental Analysis](https://www.bartleby.com/isbn_cover_images/9781305577213/9781305577213_smallCoverImage.gif)
![Organic Chemistry](https://www.bartleby.com/isbn_cover_images/9780078021558/9780078021558_smallCoverImage.gif)
![Chemistry: Principles and Reactions](https://www.bartleby.com/isbn_cover_images/9781305079373/9781305079373_smallCoverImage.gif)
![Elementary Principles of Chemical Processes, Bind…](https://www.bartleby.com/isbn_cover_images/9781118431221/9781118431221_smallCoverImage.gif)